Prelude Therapeutics Cash Flow Statement (2019-2026) | PRLD

Cash Flow Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income (Quarter)
-27.92M-30.84M-33.01M-30.29M-29.46M-30.41M-33.38M-29.11M-32.40M-33.38M-37.38M-34.34M-37.16M-34.38M-33.83M-34.61M-32.19M-20.42M-17.35M-14.18M
Share-based Compensation (Quarter)
4.24M7.03M5.78M6.83M6.03M6.44M5.84M6.26M6.73M6.71M5.91M5.55M6.10M5.93M3.77M3.83M3.81M2.42M1.84M2.00M
Gains from Sales and Divestitures (Quarter)
0.37M0.50M0.60M0.10M0.23M0.32M0.39M0.00M0.04M0.05M0.06M0.01M0.03M0.03M0.04M0.01M0.02M0.03M0.04M0.06M
Gains from Investment Securities (Quarter)
6.77M2.23M-1.28M1.65M0.85M9.20M0.88M1.29M0.27M0.00M0.83M0.00M0.00M0.00M0.01M0.00M0.00M15.50M-0.04M0.58M
Non-cash Items (Quarter)
131.10M2.09M25.10M11.30M2.74M12.10M3.59M9.10M5.40M5.58M6.08M6.40M4.00M0.50M0.10M8.82M9.53M9.63M7.50M10.10M
Cash from Operations (Quarter)
-19.91M-21.77M-25.70M-21.89M-18.47M-20.44M-22.93M-30.13M-27.67M-25.68M-23.58M-31.79M-23.06M-27.30M-20.74M-34.23M-26.07M-19.11M23.12M-21.68M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)
0.29M0.36M-2.29M0.41M0.43M-3.61M0.18M0.43M0.37M0.52M0.61M0.41M0.40M0.39M3.44M-0.08M0.85M-0.58M0.19M0.39M
Depreciation & Amortization (CF) (Quarter)
0.20M0.27M0.29M0.31M0.32M0.34M0.36M0.28M0.28M0.28M0.33M0.43M0.45M0.41M0.49M0.43M0.43M0.42M0.42M0.39M
Change in Working Capital
Change in Account Payables (Quarter)
1.73M4.51M-3.93M0.00M-0.84M3.73M-3.24M0.37M-1.71M-0.47M-0.47M0.63M1.08M-0.21M1.81M-1.91M-0.85M-2.43M1.27M-1.88M
Change in Accured Expenses (Quarter)
0.52M0.46M2.86M-0.40M0.90M3.17M3.17M-1.90M-2.59M2.62M4.39M-5.69M1.23M2.09M1.57M-3.97M1.87M-0.37M-0.52M-6.60M
Other Working Capital Changes (Quarter)
1.22M2.07M-1.17M0.42M-1.98M2.84M0.43M0.35M2.19M-0.49M-0.43M-0.64M-0.19M-0.08M0.92M1.05M0.33M-0.29M34.44M0.07M
Investing Activities
Capital Expenditures (Quarter)
1.28M0.66M0.30M0.35M1.36M0.92M-2.54M0.81M0.98M0.59M1.13M0.29M0.36M0.06M-0.70M0.05M0.02M
Change in Acquisitions & Divestments (Quarter)
42.50M45.08M81.36M35.00M26.00M46.50M49.75M68.25M37.00M34.36M42.79M29.50M71.70M36.20M40.09M6.40M8.50M
Cash from Investing Activities (Quarter)
-0.38M-260.63M-1.80M0.15M58.58M21.61M1.35M18.00M-75.43M15.04M7.74M31.22M26.12M10.73M22.12M62.19M11.52M40.09M-60.34M8.50M
Financing Activities
Other financing activities (Quarter)
4.24M7.03M5.78M6.83M6.03M6.44M5.84M6.26M6.73M6.71M5.91M5.55M6.10M5.93M3.83M3.81M2.42M11.91M0.29M
Cash from Financing Activities (Quarter)
0.42M0.71M1.95M41.55M-41.04M0.15M0.15M-0.27M111.34M0.09M25.24M-0.01M0.06M-0.13M-0.03M-0.16M0.04M-0.01M24.94M-0.31M
Additional items
Change in Cash (Quarter)
-19.87M-281.69M-25.55M19.81M-0.93M1.32M-21.42M-12.40M8.24M-10.55M9.39M-0.58M3.12M-16.69M1.34M27.80M-14.52M20.97M-12.28M-13.50M
Free Cash Flow (Quarter)
-21.19M-22.43M-26.00M-22.25M-19.82M-21.36M-20.39M-30.94M-28.65M-26.27M-24.71M-32.08M-23.42M-27.36M-20.04M-34.28M-26.09M-19.11M23.12M-21.68M
Net Cash Flow (Quarter)
-19.87M-281.69M-25.55M19.81M-0.93M1.32M-21.42M-12.40M8.24M-10.55M9.39M-0.58M3.12M-16.69M1.34M27.80M-14.52M20.97M-12.28M-13.50M